At the news
? BULLISHIMPACT 7/10 8-K filed May 12, 2026 at 07:14 ET
Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC for ER+/HER2- breast cancer. Arvinas and Pfizer will receive $85 million in upfront and near-term payments, split evenly, with up to $320 million in milestones and tiered mid-teens to mid-20s royalties. Rigel takes over U.S. commercialization and owns global rights with sublicensing ability.
- Arvinas and Pfizer entered a license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (vepdegestrant), an FDA-approved PROTAC for ER+/HER2- advanced breast cancer.
- Rigel will pay $70 million upfront and $15 million upon completion of select development/manufacturing transition activities, split evenly between Arvinas and Pfizer.
- Arvinas and Pfizer are eligible for up to $320 million in development, regulatory, and commercial milestone payments plus tiered royalties in the mid-teens to mid-20s on worldwide net sales.
- Rigel will contribute up to $40 million toward ongoing development activities.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access